| Literature DB >> 28613071 |
Hong-Jie Zhang1, Emily Rumschlag-Booms2, Yi-Fu Guan1, Dong-Ying Wang1, Kang-Lun Liu1, Wan-Fei Li1, Van H Nguyen3, Nguyen M Cuong4, Djaja D Soejarto5, Harry H S Fong5, Lijun Rong2.
Abstract
Justicia gendarussa, a medicinal plant collected in Vietnam, was identified as a potent anti-HIV-1 active lead from the evaluation of over 4500 plant extracts. Bioassay-guided separation of the extracts of the stems and roots of this plant led to the isolation of an anti-HIV arylnaphthalene lignan (ANL) glycoside, patentiflorin A (1). Evaluation of the compound against both the M- and T-tropic HIV-1 isolates showed it to possess a significantly higher inhibition effect than the clinically used anti-HIV drug AZT. Patentiflorin A and two congeners were synthesized, de novo, as an efficient strategy for resupply as well as for further structural modification of the anti-HIV ANL glycosides in the search for drug leads. Subsequently, it was determined that the presence of a quinovopyranosyloxy group in the structure is likely essential to retain the high degree of anti-HIV activity of this type of compounds. Patentiflorin A was further investigated against the HIV-1 gene expression of the R/U5 and U5/gag transcripts, and the data showed that the compound acts as a potential inhibitor of HIV-1 reverse transcription. Importantly, the compound displayed potent inhibitory activity against drug-resistant HIV-1 isolates of both the nucleotide analogue (AZT) and non-nucleotide analogue (nevaripine). Thus, the ANL glycosides have the potential to be developed as novel anti-HIV drugs.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28613071 DOI: 10.1021/acs.jnatprod.7b00004
Source DB: PubMed Journal: J Nat Prod ISSN: 0163-3864 Impact factor: 4.050